Q-omics provides the consensus-scored MIR505 profile across patient tissues and cancer cell-line models. MIR505 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, MIR505 is differentially expressed in 1, with the highest sampling consensus in COAD. Additionally, MIR505 RNA expression shows 9,271 significant gene co-expression associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRP, COAD, and BRCA as cancer lineages where MIR505 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR505 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR505 survival associations across molecular data types. MIR505 RNA expression shows survival associations in the most cancer types (9), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR505 RNA expression–survival associations across cancer types. High MIR505 expression shows unfavorable associations in KIRP, THCA, MESO, LUSC, OV and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for MIR505 RNA expression.
This table summarizes MIR505 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR505. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR505 shows higher tumor expression in COAD. The COAD box plot shows higher MIR505 RNA expression in tumor versus normal tissue (log2 FC = +0.122, t-test p = .049).
This table shows molecular features associated with MIR505 in patient tissues and cancer cell lines. In patient samples, MIR505 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
